These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 16239414)

  • 1. Paclitaxel-eluting stents in coronary artery disease.
    Nawarskas JJ; Osborn LA
    Am J Health Syst Pharm; 2005 Nov; 62(21):2241-51. PubMed ID: 16239414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.
    Stone GW; Ellis SG; Cannon L; Mann JT; Greenberg JD; Spriggs D; O'Shaughnessy CD; DeMaio S; Hall P; Popma JJ; Koglin J; Russell ME;
    JAMA; 2005 Sep; 294(10):1215-23. PubMed ID: 16160130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The paclitaxel-eluting stent in percutaneous coronary intervention: part I: background and clinical comparison to bare metal stents.
    Gruchalla KJ; Nawarskas JJ
    Cardiol Rev; 2006; 14(2):88-98. PubMed ID: 16493246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
    Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
    N Engl J Med; 2004 Jan; 350(3):221-31. PubMed ID: 14724301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions.
    Waugh J; Wagstaff AJ
    Am J Cardiovasc Drugs; 2004; 4(4):257-68. PubMed ID: 15285700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
    Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW;
    J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
    Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
    JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
    Stone GW; Ellis SG; O'Shaughnessy CD; Martin SL; Satler L; McGarry T; Turco MA; Kereiakes DJ; Kelley L; Popma JJ; Russell ME;
    JAMA; 2006 Mar; 295(11):1253-63. PubMed ID: 16531618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis.
    Doggrell SA
    Expert Opin Pharmacother; 2004 Nov; 5(11):2209-20. PubMed ID: 15500367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation.
    Herdeg C; Göhring-Frischholz K; Haase KK; Geisler T; Zürn C; Hartmann U; Wöhrle J; Nusser T; Dippon J; May AE; Gawaz M
    Circ Cardiovasc Interv; 2009 Aug; 2(4):294-301. PubMed ID: 20031731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives of drug-eluting stents: the next revolution.
    Moses JW; Kipshidze N; Leon MB
    Am J Cardiovasc Drugs; 2002; 2(3):163-72. PubMed ID: 14727979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
    Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
    Kastrati A; Mehilli J; von Beckerath N; Dibra A; Hausleiter J; Pache J; Schühlen H; Schmitt C; Dirschinger J; Schömig A;
    JAMA; 2005 Jan; 293(2):165-71. PubMed ID: 15644543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.
    Hermiller JB; Raizner A; Cannon L; Gurbel PA; Kutcher MA; Wong SC; Russell ME; Ellis SG; Mehran R; Stone GW;
    J Am Coll Cardiol; 2005 Apr; 45(8):1172-9. PubMed ID: 15837245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial).
    Nikolsky E; Kosinski E; Mishkel GJ; Kimmelstiel C; McGarry TF; Mehran R; Leon MB; Russell ME; Ellis SG; Stone GW
    Am J Cardiol; 2005 Mar; 95(6):709-15. PubMed ID: 15757595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.